Promising drug cocktail eyed for Tough-to-Treat urinary cancer
NCT ID NCT07633353
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how well a combination of two drugs (enfortumab vedotin and pembrolizumab) works as a first treatment for people with advanced upper tract urothelial carcinoma, a rare cancer of the urinary tract. Researchers will track 50 patients in France to see how many respond to treatment and how long they live without the cancer growing. They will also check for side effects and look at certain markers in the tumors that might predict who benefits most.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- enfortumab vedotin plus pembrolizumab
- What this could lead to
- If successful, this could confirm that the drug combination is an effective first-line treatment for this rare type of urinary tract cancer.
- What could go wrong
- This is a small, observational study (50 patients) with no control group, so results may not be definitive. Side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
adults \> 18 years old with histologically confirmed metastatic or locally advanced urothelial carcinoma
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * advanced upper tract urothelial carcinoma treated with enfortumab vedotin and pembrolizumab * at least one infusion of the treatment Exclusion Criteria: * patient previously treated with immune checkpoint inhibitor * patient previously treated with systemic treatment for advance UTUC
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced upper tract urothelial carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Hospitalier Universitaire
Nîmes, 30000, France